The von Hippel-Lindau (VHL) Cullin RING E3 ligase is an essential enzyme in the ubiquitin-
proteasome system that recruits substrates such as the hypoxia inducible factor for …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, is overexpressed and
activated in many cancer types. FAK regulates diverse cellular processes, including growth …

Methods to direct the degradation of protein targets with proximity-inducing molecules that
coopt the cellular degradation machinery are advancing in leaps and bounds, and diverse …

Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed
and activated in several advanced-stage solid cancers. FAK promotes tumour progression …

Focal adhesion kinase (FAK) is a key regulator of growth factor receptor-and integrin-
mediated signals, governing fundamental processes in normal and cancer cells through its …

Focal adhesion kinase (FAK) is a key mediator of tumour progression and metastasis. To
date, clinical trials of FAK inhibitors have reported disappointing efficacy for oncology …

Focal adhesion kinase (FAK) is a cytoplasmic nonreceptor tyrosine kinase that enables
activation by growth factor receptors or integrins in various types of human cancers. The …

Focal adhesion kinase (FAK) is considered as a pivotal intracellular non-receptor tyrosine
kinase, and has garnered significant attention as a promising target for anticancer drug …

Focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, is a vital
participant in primary cellular functions, such as proliferation, survival, migration, and …